Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

PP405 is expected to work for hair regrowth by reactivating stem cells in hair follicles, with FDA approval anticipated in 2027-28. Users express both optimism and skepticism about its effectiveness and the lengthy approval process.

Laser caps are found to be more effective than 5% minoxidil for treating hair loss, and when combined with minoxidil, they are even more effective. Some users report positive results with laser treatments, while others see no change; the devices are FDA approved, but opinions on their efficacy vary.

A user questions the authenticity of a cheap minoxidil product due to packaging errors and unusual smell, considering returning it. They also reference an FDA report for further information.

Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. There is skepticism about claims of a breakthrough, despite FDA approval for human trials.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

Neofollics lotion is discussed as a hair loss treatment, but users report it is ineffective and not supported by strong evidence. Users suggest sticking to FDA-approved treatments like Minoxidil and Finasteride.

Microneedling with exosomes is being considered for hair regrowth, but concerns exist about their effectiveness and safety, especially since exosomes degrade quickly and lack FDA approval. The user is seeking alternatives for non-responders to minoxidil and dutasteride, as exosomes may not provide additional benefits.

Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.

Finasteride is preferred over dutasteride due to its longer history, more research, and FDA approval, despite dutasteride being more potent. Users report varied side effects, influencing personal treatment choices.

The user shared progress pictures showing significant hair regrowth from using finasteride, RU58841, and liquid minoxidil, emphasizing the importance of consistency. They noted that RU58841, a research chemical not FDA-approved, was effective when applied topically but warned of potential heart-related side effects.

Nizoral shampoo effectively reduces scalp itchiness and dandruff, particularly for those using minoxidil, and may promote hair growth despite not being FDA-approved for this purpose. Users report significant improvements in scalp health and reduced itchiness with regular use.

People often turn to natural remedies like saw palmetto and rosemary oil for hair loss, but these are not as effective as FDA-approved treatments like finasteride and minoxidil. Some users express concerns about potential side effects of finasteride, while others share positive experiences with it.

RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.

RU58841 is considered an effective topical anti-androgen for hair loss, often used with minoxidil. Concerns exist about its purity and sourcing since it's not FDA-approved.

Nanoxidil is discussed as a potential alternative to Minoxidil for hair loss, with some users reporting better results and improved hair strength. However, concerns about its lack of FDA approval and potential scalp dryness are noted.

Aminexil is similar to Minoxidil but less effective and not widely used, with some users reporting minor regrowth. It is not FDA-approved and has been removed from some products, though some people still use it, often in combination with Minoxidil.

RU58841 is discussed as a hair loss treatment, with concerns about potential heart risks and systemic side effects. Some users suggest trying FDA-approved treatments like finasteride first, while others debate the safety and cost-effectiveness of RU58841.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.

People are discussing why some choose finasteride over dutasteride for hair loss, noting that while dutasteride is more effective, it's also more expensive, less researched, and potentially has more side effects. Some users shared personal experiences with side effects from both drugs, and others mentioned that finasteride is FDA approved for hair loss, while dutasteride is not, except in Japan.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

Microneedling with minoxidil and finasteride greatly improves hair regrowth. Using 0.5mm depth every other day boosts minoxidil absorption without side effects.